Roche Resources is intended for UK Healthcare Professionals only. By entering this site you are confirming that you are a UK Healthcare professional.

OCREVUS SC injection is indicated for the treatment of adult patients with1:

  • relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features
  • early primary progressive multiple sclerosis (PPMS) in terms of disease duration and level of disability, and with imaging features characteristic of inflammatory activity

g
Prescribing Information OCREVUS SC
Prescribing Information OCREVUS IV
Nurses at the Limits Symposium Recordings

Recorded from the ‘Nurses at the Limits’ MS conference Roche symposium, these two videos feature MS nurses sharing their detailed experiences and knowledge about implementing OCREVUS SC injection. The Nurses at the Limits conference is a two-day meeting that brings together a range of topics and speakers which are directly relevant to the challenges facing MS Nurses today.

Alexandra Strong, Lead Clinical Nurse Specialist 

Morriston Hospital, Swansea

 

Alexandra provides first hand insights into how the team prepared the trust to commence subcutaneous administration of OCREVUS, the necessary equipment used, patient experiences, and key practical considerations.

Jenny Slough, Lead MS Clinical Nurse Specialist

The National Hospital for Neurology and Neurosurgery

 

Jenny discusses valuable insights into starting using OCREVUS SC injections in their services, patient experiences, and the practicalities of administering the treatment.

Reference:

1. OCREVUS SC Summary of Product Characteristics (SmPC)
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. You can also report via the free Yellow Card app available from the Apple App Store or Google Play Store. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.
Adverse reactions should be reported by brand name and batch number.
You are about to leave the rocheresources.co.uk environment and will be redirected to another site or resource which may contain information not intended for a UK audience. Roche Products Limited does not endorse or accept liability for sites or resources controlled by third parties.